Position in ABVX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,642,795
+$3,353,966 QoQ
Shares Held
27,336
+703.5% QoQ
Ownership
0.031%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#120
of 299 holders
Holding Since
Sep 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABVX Over Time
Shares Held
Position Value (USD)
Derivatives in ABVX
reported options exposure · as of Jun 30, 2026CallValue
$3,331,500
CallShares
25,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Marex Group plc holds $88,179,553 across 55 Biotechnology names. ABVX ranks #8 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TGTX |
Tg Therapeutics, Inc.
|
276,178 | $15,173,219 | |
| 2 | SANA |
Sana Biotechnology, Inc.
|
3,989,100 | $13,921,959 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
623,600 | $10,551,312 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
170,584 | $9,303,650 | |
| 5 | DNLI |
Denali Therapeutics Inc.
|
295,631 | $7,603,629 | |
| 6 | MRNA |
Moderna, Inc.
|
88,575 | $6,202,907 | |
| 7 | QURE |
uniQure N.V.
|
81,500 | $3,753,890 | |
| 8 | ABVX |
Abivax S.A.
This page
|
27,336 | $3,642,795 |
All Filings in ABVX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,642,795 | 27,336 | Shares | Defined | 2026-08-14 | |
| 2026-06-30 | $3,331,500 | 25,000 | Call | Defined | 2026-08-14 | |
| 2025-09-30 | $288,829 | 3,402 | Shares | Defined | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||